Most Clicked StoriesMore >


Roche signs cancer immunotherapy deal with Curadev Pharma

BIO SmartBrief | Apr 21, 2015

Roche and Curadev Pharma agreed to collaborate in the development and marketing of IDO1 and TDO inhibitors, enzymes responsible for mediating immune suppression caused by cancer, in a deal that could be worth more than $555 million. Curadev will receive an upfront payment of $25 million and milestone payments of up to $530 million. Genetic Engineering & Biotechnology News (04/20)


Mylan is target of $40B acquisition bid from Teva

BIO SmartBrief | Apr 22, 2015

Merck submits application to market Keytruda for lung cancer

BIO SmartBrief | Apr 20, 2015

DuPont purchases Taxon Biosciences

BIO SmartBrief | Apr 24, 2015

Dr. Oz responds to criticism on biotech food labeling stance

BIO SmartBrief | Apr 24, 2015

AstraZeneca unit to collaborate with Juno on cancer immunotherapies

BIO SmartBrief | Apr 24, 2015

Takeda signs $268M deal with Kyoto University for stem cell therapies

BIO SmartBrief | Apr 20, 2015

Concordia wraps up $1.2B purchase of Covis

BIO SmartBrief | Apr 23, 2015

Ovarian cancer drug from CanTx gains orphan status

BIO SmartBrief | Apr 23, 2015

Analysts predict continued pharma dealmaking

BIO SmartBrief | Apr 22, 2015


Find BIO SmartBrief Issues by Date:



BIO News More >


BIO International Convention -- Register Now

BIO SmartBrief | Apr 24, 2015

Secure document sharing services optimized for life science organizations

BIO SmartBrief | Apr 16, 2015

Faster & better connections with quality R&D vendors

BIO SmartBrief | Apr 16, 2015

Industrial biotechnology with a French twist!

BIO SmartBrief | Apr 15, 2015

Are you looking for top biotech talent? Or looking for a biotech job?

BIO SmartBrief | Apr 14, 2015




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more